title: A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension.
abstract: BACKGROUND
  Loop diuretics are the drugs of choice for the treatment of hypertension in chronic renal failure patients. However, the adaptive changes in the distal nephron and the short half-life of these drugs may decrease their long-term efficacy. Thiazides are not believed to be efficient in advanced renal failure, but this is debated.
  
  
  METHODS
  We compared the efficacy of long-acting furosemide (60 mg/day) and hydrochlorothiazide (25 mg/day) in a double-blind, randomized crossover trial in seven patients with severe renal failure and hypertension (seven men, 54+/-10 years old). The primary end-points were sodium and chloride fractional excretions after 1 month of each diuretic and then after their combination. During the trial, other treatments and the diet were controlled.
  
  
  RESULTS
  A trend towards an increase in the fractional excretion of sodium and of chloride was observed with furosemide, but the difference did not reach the level of statistical significance (P = NS). Hydrochlorothiazide significantly increased fractional excretion of sodium and chloride from 3.7+/-0.9 to 5.5+/-0.3 and from 3.9+/-0.19 to 6.5+/-0.3, respectively (P<0.05). The combination of the two diuretics had no additional effect on the increase in sodium and chloride fractional excretion. Furosemide, hydrochlorothiazide and the combination of the two diuretics decreased mean arterial blood pressure by the same extent from 112 to 97, 99 and 97 mmHg, respectively (P<0.05).
  
  
  CONCLUSIONS
  Hydrochlorothiazide increased the fractional excretion of sodium and chloride more than furosemide did in hypertensive severe renal failure patients. Mean arterial blood pressure decreased by the same amount with both diuretics. Combining furosemide and hydrochlorothiazide did not increase the efficacy of hydrochlorothiazide.
authors.affiliation: Service de Néphrologie-Hémodialyse-Transplantation, Hôpital de la Conception, 147 Bd Baille, 13385 Marseille Cedex 5, France. bdussol@mail.ap-hm.fr
authors.forename: Bertrand
authors.initials: B
authors.lastname: Dussol
authors.forename: Julie
authors.initials: J
authors.lastname: Moussi-Frances
authors.forename: Sophie
authors.initials: S
authors.lastname: Morange
authors.forename: Claude
authors.initials: C
authors.lastname: Somma-Delpero
authors.forename: Olivier
authors.initials: O
authors.lastname: Mundler
authors.forename: Yvon
authors.initials: Y
authors.lastname: Berland
mesh_terms: D000328:Adult; D000368:Aged; D002712:Chlorides / Q000652:urine; D018592:Cross-Over Studies; D004232:Diuretics; D004311:Double-Blind Method; D005665:Furosemide / Q000627:therapeutic use*; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use*; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D012964:Sodium / Q000652:urine; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use
chemical_list: D002712:Chlorides; D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors; D006852:Hydrochlorothiazide; D005665:Furosemide; D012964:Sodium